317 related articles for article (PubMed ID: 33907188)
1. Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis.
Hieronymus F; Lisinski A; Eriksson E; Østergaard SD
Transl Psychiatry; 2021 Apr; 11(1):249. PubMed ID: 33907188
[TBL] [Abstract][Full Text] [Related]
2. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
[TBL] [Abstract][Full Text] [Related]
3. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
[TBL] [Abstract][Full Text] [Related]
4. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
5. Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
Lisinski A; Hieronymus F; Nilsson S; Eriksson E
Transl Psychiatry; 2022 Apr; 12(1):160. PubMed ID: 35422023
[TBL] [Abstract][Full Text] [Related]
6. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
8. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
Hieronymus F; Emilsson JF; Nilsson S; Eriksson E
Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants for people with epilepsy and depression.
Maguire MJ; Weston J; Singh J; Marson AG
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Mol Psychiatry; 2018 Aug; 23(8):1731-1736. PubMed ID: 29155804
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.
Hengartner MP; Jakobsen JC; Sørensen A; Plöderl M
PLoS One; 2020; 15(2):e0229381. PubMed ID: 32101579
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.
Barros BR; Schacht A; Happich M; Televantou F; Berggren L; Walker DJ; Dueñas HJ
Prim Care Companion CNS Disord; 2014; 16(5):. PubMed ID: 25667808
[TBL] [Abstract][Full Text] [Related]
14. Antidepressants for people with epilepsy and depression.
Maguire MJ; Marson AG; Nevitt SJ
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
[TBL] [Abstract][Full Text] [Related]
15. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.
Bobo WV; Angleró GC; Jenkins G; Hall-Flavin DK; Weinshilboum R; Biernacka JM
Hum Psychopharmacol; 2016 May; 31(3):185-92. PubMed ID: 26999588
[TBL] [Abstract][Full Text] [Related]
16. Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials.
Hieronymus F; Lisinski A; Hieronymus M; Näslund J; Eriksson E; Østergaard SD
Acta Psychiatr Scand; 2021 Sep; 144(3):300-309. PubMed ID: 34146343
[TBL] [Abstract][Full Text] [Related]
17. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Näslund J; Hieronymus F; Emilsson JF; Lisinski A; Nilsson S; Eriksson E
Acta Psychiatr Scand; 2017 Oct; 136(4):343-351. PubMed ID: 28859218
[TBL] [Abstract][Full Text] [Related]
18. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
